Replidyne continues their charge towards the planned 4Q05 NDA filing for Faropenem, an antibiotic for the treatment of respiratory tract infections. To aid these efforts the company has just closed on a $62.5 million Series D financing led by several new investors including: Duquesne Capital Management, Healthcare Investment Partners and MDS Life Sciences. Also participating in this financing round were existing investors HealthCare Ventures, TPG Ventures, Morgenthaler Ventures, Perseus-Soros BioPharmaceutical Fund, Sequel Venture Partners, Temasek Holdings and Quintiles Transnational.
This latest funding shall enable the anticipated Faropenem product launch in 2006 pending FDA final approval, in addition to enabling REP8839, an antibiotic for the treatment of antibiotic-resistant skin and staph infection causing bacteria, to be brought into clinical trials.
Might we see a 2006 IPO?
Friday, September 09, 2005
Replidyne – NDA or Bust!
Subscribe to:
Post Comments (Atom)
1 comment:
Hi Adam, Out surfing for information on treatment for boils & happened upon your site. While this post wasn't exactly spot on, it did strike a note with me. Thank you for the really good read.
Post a Comment